Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System

Docetaxel (DTX) is classified as a class IV drug that exhibits poor aqueous solubility (6–7 µg/mL in water) and permeability (P-glycoprotein substrate). The main objective of this study was to construct, characterize, and evaluate docetaxel loaded nanomicellar formulation <i>in vitro</i>...

Full description

Bibliographic Details
Main Authors: Meshal Alshamrani, Navid J. Ayon, Abdullah Alsalhi, Omowumi Akinjole
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Life
Subjects:
Online Access:https://www.mdpi.com/2075-1729/12/4/485
_version_ 1827628038350700544
author Meshal Alshamrani
Navid J. Ayon
Abdullah Alsalhi
Omowumi Akinjole
author_facet Meshal Alshamrani
Navid J. Ayon
Abdullah Alsalhi
Omowumi Akinjole
author_sort Meshal Alshamrani
collection DOAJ
description Docetaxel (DTX) is classified as a class IV drug that exhibits poor aqueous solubility (6–7 µg/mL in water) and permeability (P-glycoprotein substrate). The main objective of this study was to construct, characterize, and evaluate docetaxel loaded nanomicellar formulation <i>in vitro</i> for oral delivery to enhance the absorption and bioavailability of DTX, as well as to circumvent P-gp efflux inhibition. Formulations were prepared with two polymeric surfactants, hydrogenated castor oil-40 (HCO-40) and D-α-Tocopherol polyethylene glycol 1000 succinate (VIT E TPGS) with solvent evaporation technique, and the resulting DTX nanomicellar formulations were characterized by proton nuclear magnetic resonance spectroscopy (1H NMR), Fourier Transform Infrared Spectroscopy (FT–IR), X-ray powder diffraction (XRD), and transmission electron microscopy (TEM). Proton NMR, FT–IR, and XRD data indicated that DTX was completely encapsulated within the hydrophobic core of the nanomicelles in its amorphous state. TEM data revealed a smooth spherical shape of the nanomicellar formulation. The optimized formulation (F-2) possessed a mean diameter of 13.42 nm, a zeta potential of −0.19 mV, with a 99.3% entrapment efficiency. Dilution stability study indicated that nanomicelles were stable up to 100-fold dilution with minimal change in size, poly dispersity index (PDI), and zeta potential. <i>In vitro</i> cytotoxicity study revealed higher anticancer activity of DTX nanomicelles at 5 µM compared to the native drug against breast cancer cell line (MCF-7) cells. The LC–MS data confirmed the chemical stability of DTX within the nanomicelles. <i>In vitro</i> drug release study demonstrated faster dissolution of DTX from the nanomicelles compared to the naked drug. Our experimental results exhibit that nanomicelles could be a drug delivery system of choice to encapsulate drugs with low aqueous solubility and permeability that can preserve the stability of the active constituents to provide anticancer activity.
first_indexed 2024-03-09T13:25:11Z
format Article
id doaj.art-46192b44cc154c5fa1513f401c76d638
institution Directory Open Access Journal
issn 2075-1729
language English
last_indexed 2024-03-09T13:25:11Z
publishDate 2022-03-01
publisher MDPI AG
record_format Article
series Life
spelling doaj.art-46192b44cc154c5fa1513f401c76d6382023-11-30T21:24:46ZengMDPI AGLife2075-17292022-03-0112448510.3390/life12040485Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic SystemMeshal Alshamrani0Navid J. Ayon1Abdullah Alsalhi2Omowumi Akinjole3Department of Pharmaceutics, College of Pharmacy, Jazan University, P.O. Box 114, Jazan 45142, Saudi ArabiaProteomics Center of Excellence, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USADepartment of Pharmaceutics, College of Pharmacy, Jazan University, P.O. Box 114, Jazan 45142, Saudi ArabiaLaboratory of Future Nanomedicines and Theoretical Chronopharmaceutics, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, USADocetaxel (DTX) is classified as a class IV drug that exhibits poor aqueous solubility (6–7 µg/mL in water) and permeability (P-glycoprotein substrate). The main objective of this study was to construct, characterize, and evaluate docetaxel loaded nanomicellar formulation <i>in vitro</i> for oral delivery to enhance the absorption and bioavailability of DTX, as well as to circumvent P-gp efflux inhibition. Formulations were prepared with two polymeric surfactants, hydrogenated castor oil-40 (HCO-40) and D-α-Tocopherol polyethylene glycol 1000 succinate (VIT E TPGS) with solvent evaporation technique, and the resulting DTX nanomicellar formulations were characterized by proton nuclear magnetic resonance spectroscopy (1H NMR), Fourier Transform Infrared Spectroscopy (FT–IR), X-ray powder diffraction (XRD), and transmission electron microscopy (TEM). Proton NMR, FT–IR, and XRD data indicated that DTX was completely encapsulated within the hydrophobic core of the nanomicelles in its amorphous state. TEM data revealed a smooth spherical shape of the nanomicellar formulation. The optimized formulation (F-2) possessed a mean diameter of 13.42 nm, a zeta potential of −0.19 mV, with a 99.3% entrapment efficiency. Dilution stability study indicated that nanomicelles were stable up to 100-fold dilution with minimal change in size, poly dispersity index (PDI), and zeta potential. <i>In vitro</i> cytotoxicity study revealed higher anticancer activity of DTX nanomicelles at 5 µM compared to the native drug against breast cancer cell line (MCF-7) cells. The LC–MS data confirmed the chemical stability of DTX within the nanomicelles. <i>In vitro</i> drug release study demonstrated faster dissolution of DTX from the nanomicelles compared to the naked drug. Our experimental results exhibit that nanomicelles could be a drug delivery system of choice to encapsulate drugs with low aqueous solubility and permeability that can preserve the stability of the active constituents to provide anticancer activity.https://www.mdpi.com/2075-1729/12/4/485nanomicellesvitamin E TPGS deliveryenhanced solubilityanticancer activitybreast cancerdocetaxel
spellingShingle Meshal Alshamrani
Navid J. Ayon
Abdullah Alsalhi
Omowumi Akinjole
Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System
Life
nanomicelles
vitamin E TPGS delivery
enhanced solubility
anticancer activity
breast cancer
docetaxel
title Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System
title_full Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System
title_fullStr Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System
title_full_unstemmed Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System
title_short Self-Assembled Nanomicellar Formulation of Docetaxel as a Potential Breast Cancer Chemotherapeutic System
title_sort self assembled nanomicellar formulation of docetaxel as a potential breast cancer chemotherapeutic system
topic nanomicelles
vitamin E TPGS delivery
enhanced solubility
anticancer activity
breast cancer
docetaxel
url https://www.mdpi.com/2075-1729/12/4/485
work_keys_str_mv AT meshalalshamrani selfassemblednanomicellarformulationofdocetaxelasapotentialbreastcancerchemotherapeuticsystem
AT navidjayon selfassemblednanomicellarformulationofdocetaxelasapotentialbreastcancerchemotherapeuticsystem
AT abdullahalsalhi selfassemblednanomicellarformulationofdocetaxelasapotentialbreastcancerchemotherapeuticsystem
AT omowumiakinjole selfassemblednanomicellarformulationofdocetaxelasapotentialbreastcancerchemotherapeuticsystem